

Antimicrobial Efficacy of Biogenic Manganese Oxide Nanoparticles Against *Klebsiella pneumoniae*: A Novel Approach to Combat Antibiotic Resistance

Muhammad Noman^{*1}, Areesa Ghazal², Akbar Ali³, Qaria Yameen², Syeda Taseer Zahra Naqvi², Aasia Bibi², Novera Mushtaq², Hafiza Sania Younas⁴

¹Department of Pathology, Faculty of Medicine and Allied Health Sciences, The University of Faisalabad, Pakistan

²Department of Chemistry, Faculty of Science, Ghazi University, Dera Ghazi Khan, Pakistan

³Department of Primary & Secondary Healthcare Lahore, Ministry of Health, Govt. of Punjab, Pakistan

⁴Department of Microbiology, Faculty of Life Sciences, Government College University, Faisalabad, Pakistan

*Corresponding author's email address: muhammadnoman.mls1@gmail.com

(Received, 24th March 2025, Accepted 22nd July 2025, Published 31st July 2025)

Abstract: The rise of multidrug-resistant (MDR) bacteria has emerged as a critical global health concern, significantly impeding effective infection management. Conventional antibiotics are increasingly failing against pathogens such as *Klebsiella pneumoniae*, which is notorious for its resistance and prevalence in nosocomial infections. This has necessitated the exploration of alternative antimicrobial strategies. **Objective:** To evaluate the antibacterial, antibiofilm, and cytotoxic effects of biogenically synthesized manganese oxide nanoparticles (MnO NPs) against multidrug-resistant *Klebsiella pneumoniae*. **Methods:** This experimental study involved the biosynthesis of manganese oxide nanoparticles followed by their evaluation against *Klebsiella pneumoniae*. Antibacterial activity was assessed using the agar well diffusion assay. Minimum inhibitory concentration (MIC) was determined via the broth dilution method. Antibiofilm activity was quantified using the crystal violet microtiter plate assay. The effect of sub-inhibitory concentrations of MnO NPs on extracellular polymeric substances (EPS) was also studied. Cytotoxicity was evaluated using the neutral red uptake assay and morphological analysis of HepG2 human liver cell lines. **Results:** Manganese oxide nanoparticles demonstrated notable antibacterial activity with clear zones of inhibition in agar diffusion assays. MIC testing revealed significant growth inhibition of *K. pneumoniae* at defined nanoparticle concentrations. MnO NPs also significantly reduced biofilm formation and disrupted EPS production at sub-MIC levels. Cytotoxicity assays indicated that MnO NPs exhibited minimal toxic effects on HepG2 cells at effective antimicrobial concentrations, suggesting good biocompatibility. **Conclusion:** Biogenically synthesized manganese oxide nanoparticles possess potent antibacterial and antibiofilm activity against *Klebsiella pneumoniae*, with minimal cytotoxicity to human liver cells. These findings suggest that MnO NPs may offer a promising alternative therapeutic approach to combat multidrug-resistant bacterial infections.

Keywords: Drug Resistance, Bacterial Nanoparticles, Manganese Compounds, *Klebsiella pneumoniae* Biofilms

[How to Cite: Noman M, Ghazal A, Ali A, Yameen Q, Naqvi STZ, Bibi A, Mushtaq N, Younas HS. Antimicrobial efficacy of biogenic manganese oxide nanoparticles against *Klebsiella pneumoniae*: a novel approach to combat antibiotic resistance. *Biol. Clin. Sci. Res. J.*, 2025; 6(7): 23-33. doi: <https://doi.org/10.54112/bcsrj.v6i7.1859>

Introduction

The emergence of bacterial resistance to antibiotics has become a significant global health concern (1). The overuse and misuse of antibiotics have accelerated the development of resistance, making it challenging to treat bacterial infections (1). *Klebsiella pneumoniae*, a Gram-negative bacterium, is a major nosocomial pathogen that has gained public interest due to its alarming multidrug resistance worldwide (2) (3). This bacterium is known for its biofilm-forming ability and various virulence factors, which contribute to its evasion of the immune system and antibiotic resistance (4).

The increasing prevalence of antibiotic resistance has led to a search for alternative therapeutic options (5). Nanotechnology has emerged as a promising solution, with nanoparticles showing potential as antimicrobial agents. Metal-based nanoparticles, in particular, have demonstrated effectiveness against antibiotic-resistant bacteria (6). The mechanism of action of these nanoparticles differs from traditional antibiotics, and they can target various biomolecules, reducing the likelihood of resistance development (7). Manganese oxide nanoparticles, with their unique physical and chemical properties, have shown promise as antimicrobial agents.

Manganese oxide nanoparticles have been found to exhibit antimicrobial activity against a range of bacteria, including *Klebsiella pneumoniae*. Their mechanism of action involves the generation of highly reactive species that damage bacterial cell membranes and walls (8) (9) (10).

Additionally, manganese oxide nanoparticles have been shown to have antioxidant properties, which could be beneficial in reducing oxidative stress in various diseases (11) (12). The use of manganese oxide nanoparticles as an alternative therapeutic option for treating bacterial infections is an area of ongoing research (13).

This study aims to evaluate the antimicrobial and antibiofilm activities of manganese oxide nanoparticles against clinical isolates of *Klebsiella pneumoniae* (14, 15). The study will also assess the minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) of manganese oxide nanoparticles, as well as their antioxidant potential and cytotoxic effects against HepG2 cell lines (16). The findings of this study may provide valuable insights into the potential use of manganese oxide nanoparticles as an alternative therapeutic option for treating *Klebsiella pneumoniae* infections (17).

Methodology

Sub-Culturing and Biochemical Characterization of Bacterial Isolates

Three clinical isolates of MDR *Klebsiella pneumoniae* obtained from the Department of Microbiology, Government College University, Faisalabad, were used in the present study. These isolates were categorized as *Klebsiella pneumoniae* A, *Klebsiella pneumoniae* B, and *Klebsiella pneumoniae* C. The bacterial culture was stabilized in LB (Luria-Bertani) broth and agar (Merck, Germany). Gram staining of



bacterial isolates was performed using the method of Becerra et al. (2016). When a primary stain is fixed with a mordant, decolorized, and then counterstained, bacteria do not retain the primary stain. Instead, they are counterstained, indicating that they are Gram-negative bacteria. First of all, a drop of water was added to the clean glass slide. A loopful of colony from the agar plate was mixed in a drop of water. The inoculating loop was moved towards the outer edges of the slide in a circular motion to create a thin smear. The smear was air-dried. Then the smear was heat fixed by gently moving the slide over the flame. The crystal violet dye was used on the smear for one minute before the slide was washed with tap water. After rinsing, the Gram's iodine was applied for one minute. The slide was again rinsed with tap water. The smear was decolorized by covering the smear with acetone for ten seconds. At last, the slide was washed and the smear was covered with a counterstain called safranin for one minute. The slide was washed, dried, and observed under an oil immersion lens of a light microscope by adding a drop of cedar wood oil on the smear. All three isolates were swabbed on MacConkey agar plates. Biochemical tests were performed to confirm the identification of different bacterial isolates.

Table 1. Biochemical tests for the identification of bacteria.

Catalase	Positive
Coagulase	Negative
Oxidase	Negative
Citrate	Positive
Indole	Negative
Methyl Red	Negative
Voges Proskauer	Positive

Set up of MacFarland Turbidity Standards

1% H₂SO₄ (sulphuric acid) and 1.175% BaCl₂.2H₂O (barium chloride dihydrate) were mixed in two different volumes to establish McFarland turbidity standards (Chapin & Lauderdale, 2003).

Table 2. Set up of McFarland Turbidity Standards

McFarland Standard No.	Volume (ml)		No. of bacteria/ml (10 ⁸) represented
	BaCl ₂ .2H ₂ O (1.175%)	H ₂ SO ₄ (1%)	
0.5	0.05	9.95	1.5
1	0.1	9.90	3
2	0.2	9.80	6
3	0.3	9.70	9
4	0.4	9.60	12
5	0.5	9.50	15

Preparation of Bacterial Culture

For preparing the bacterial inoculum, bacteria were freshly grown on nutrient agar. The isolated colonies were added to the sterile Muller-Hinton broth to make a uniform suspension. Then these broth tubes were kept in an incubator at 37°C for 24 hours. After 24 hours of incubation, the turbidity of bacteria was adjusted according to 0.5 McFarland standards (Unnisa et al., 2012). After preparation of the suspensions, they were instantly used.

Synthesis of Manganese Oxide Nanoparticles (MnO NPs)

MnO NPs were prepared by a biogenic method (Green synthesis), adopting the method of (Chatterjee et al., 2017) with some alterations. Leaf extracts of Brassica were used to synthesize the MnO NPs.

Protocol

Leaves of Brassica were rinsed in distilled water and dried until all of the water molecules were evaporated. In 50 mL of distilled water, 8.0 g of finely chopped Brassica was added. Then the mixture was boiled in a microwave oven at 100°C for 5 minutes. The solution was filtered and diluted to 10 percent for future usage. After adjusting the pH of Brassica to 6.0, KMnO₄ crystals (0.2 M concentration) were added to it. This solution was mixed for four hours, yielding a brown suspension that was then sonicated to generate a homogeneous solution. The amorphous microparticles were obtained after centrifuging and drying the resulting

solution at 100°C overnight. Finally, to acquire fine powder, the product was ground and later used for characterization.

Characterization of Manganese Oxide Nanoparticles

Metallic nanoparticles were characterized by EDX (Energy dispersive X-ray spectroscopy) and SEM (Scanning electron microscopy).



Figure 1. Leaves of Brassica




Figure 2. Steps involved in the synthesis of MnO NPs.

Assessment of Antibacterial Activity of Manganese Oxide Nanoparticles by Agar Well Diffusion Assay

Antibacterial potential was checked by the use of agar well diffusion assay following the protocol of Manyasree et al. (2018). Bacterial suspensions of all three isolates were made whose turbidity was equal to 0.5 McFarland standard. The bacterial suspensions were then swabbed onto Muller-Hinton agar plates. Then, on swabbed agar plates, 5 mm wells were made. In 100% dimethyl sulfoxide, different quantities of MnO nanoparticles (25, 50, 75, and 100µg/ml) were prepared (DMSO). DMSO was used as a control. 100µl of nanoparticle concentration was distributed into the wells. The plates were incubated for 24 hours at 37°C. The widths of zones of inhibition against all microorganisms were measured to assess antibacterial efficacy—determination of Minimum Inhibitory Concentration (MIC) of Manganese Oxide Nanoparticles. The Minimum Inhibitory Concentration (MIC) is defined as the minimum concentration of an antibacterial agent that decreases the growth rate of bacteria. MIC of MnO nanoparticles was calculated by following the broth microdilution method by Aleksh et al. (2018). The overnight cultures of bacterial isolates were prepared in normal saline, whose turbidity was compared with a 0.5 MacFarland standard. A 1500 µg/ml stock solution of manganese oxide nanoparticles was prepared in DMSO.

100 µl of Muller Hinton broth was added to all 12 wells of 96 well microtitration plate. 100 µl of the stock solution of nanoparticles was added to the first well. The nanoparticles were serially diluted in 2-fold increments up to the 10th well. Then 100 µl of bacterial suspension was dispensed into the 1st to 10th wells and then into the 12th well. The 11th acted as a positive control as it contained only broth. The 12th well acted as a negative control as it contained broth and bacterial suspension. The plate was covered with parafilm and kept in an incubator at 37°C for 24 hours. After incubation for 24 hours, the viability of bacterial cells was evaluated by using a 0.02 % solution of redox nitro-blue tetrazolium chloride (NBT) dye in methanol. The presence of viable cells was determined by the change of yellow-colored dye to blue.




Figure 3. Flow Chart of steps involved in the evaluation of antibacterial activity of MnO nanoparticles




Figure 4. Flow Chart of steps involved in the Minimum inhibitory concentration of manganese oxide nanoparticles

Determination of Minimum Bactericidal Concentration (MBC) of Manganese Oxide Nanoparticles

Minimum bactericidal concentration is the concentration of an antibacterial that completely stops bacterial growth by killing them. MBC of Manganese oxide nanoparticles was evaluated following the method of Aleksh et al. (2018) by sub-culturing the broth dilutions from the MIC well and the wells with higher concentrations of nanoparticles than MIC. With a glass spreader, 50 µl of broth from the wells of microtitration plates was distributed on Muller Hinton agar plates. These plates were kept in an incubator for 24 hours at 37°C. MBC was the minimum concentration of nanoparticles that demonstrated no observable growth on plates.

Evaluation of Antioxidant Activity of Manganese Oxide Nanoparticles

The DPPH (2,2-diphenyl-1-picrylhydrazyl) radical scavenging method was used to evaluate the antioxidant activity of MnO NPs following the method of Jacob & Rajiv (2019). The dark violet colour of DPPH solution changed to light yellow in the presence of ascorbic acid and manganese oxide nanoparticles, showing the antioxidant activities of manganese oxide nanoparticles. Manganese oxide nanoparticles and ascorbic acid were synthesized at various concentrations (50-1000 µg/ml). Dissolving 39.4 milligrams of DPPH in 1000 ml of methanol yielded a 0.1 mM DPPH solution. 3 ml of each concentration of nanoparticles and ascorbic acid were added to 2.96 ml of 0.1 mM DPPH solution. For incubation, the

mixtures were continually mixed and placed in a dark room for 20 minutes. A spectrophotometer read the absorbance of mixtures at 517 nm. 0.1 mM DPPH acted as a control, and ascorbic acid was used as a standard solution. The scavenging ability of nanoparticles was evaluated by following the formula of Otunola & Afolayan (2018). DPPH scavenging activity (%) = $[(Abs_{control} - Abs_{sample}) / (Abs_{control})] \times 100$

$Abs_{control}$ = (Absorbance of DPPH + ascorbic acid) Abs_{sample} = (Absorbance of DPPH + sample/nanoparticles)

Antibiofilm activity of Manganese Nanoparticles Microtiter plate assays were used to assess the effects of two different sub-inhibitory concentrations (0.5 x MIC) and (1 x MIC) of manganese oxide nanoparticles on biofilm development adopting the method of Shi et al. (2016) with some modification. Biofilm was quantified after staining of attached cells with crystal violet dye. Cells grown in Muller Hinton broth were diluted with fresh broth media to match the turbidity to 0.5 McFarland for preparing a standard inoculum of each isolated bacterium. In a 96-well microtitration plate, 100 µl of bacterial inoculum and 100 µl Muller Hinton broth with manganese oxide nanoparticles were dispensed. After sealing the microtitration plates with parafilm, they were put in an incubator for time intervals of 24 hours at 37°C. The non-adherent cells were removed by discarding the broth and then washing them twice with normal saline. The plates were left to dry for 30 minutes. The adhering cells were fixed with ethanol before being stained with 200 µl of 0.1 percent (v/v) crystal violet dye for 20 minutes. Following staining, the excess dye was washed out of each well three times with 200 µl of sterile normal saline. To quantify the attached cells, 200µl of glacial acetic acid (33% (v/v) was added to each well. The absorbance was measured at 594 nm using a microplate reader. Muller Hinton broth, having only bacteria, was used as positive control, while sterile Muller Hinton broth, having nanoparticles, acted as negative control. The %age of inhibition of biofilm was calculated by the formula: %age inhibition = $Control - OD_{594}$ of cells treated with MnO NPs/ OD_{594} of non-treated control x 100.




Figure 5. Flow Chart of steps involved in the evaluation of anti-biofilm activity of MnO nanoparticles

Effect of Manganese Oxide Nanoparticles on Established Biofilms

The effect of manganese oxide nanoparticles on preformed biofilms was investigated using the method of Ahmed et al. (2016) with some modifications. Biofilms were created and treated with sub-inhibitory concentrations (0.5 x MIC) and (1 x MIC) of manganese oxide nanoparticles. In a 96-well microtitration plate, 100 µl bacterial inoculum and 100 µl Muller Hinton broth were added according to the method. After sealing the microtitration plates with parafilm, they were kept in an incubator at 37°C for 24 hours. After each interval, unbound cells were removed by washing the wells twice with 200 µL of normal saline. The wells were then treated with manganese oxide nanoparticles at sub-inhibitory concentrations, with untreated wells acting as a control. Microtitration plates were incubated at 37°C for 24 hours. Washing the

cells in normal saline yielded the number of adherent cells. The cells were then stained for 20 minutes with 200 μ L of 0.1 percent (v/v) crystal violet dye.

Excess dye was washed out of the wells three times with 200 μ L of sterile normal saline after staining. The absorbance was measured at 594 nm after eluting the adherent cells with 200 μ L of 33 percent (v/v) glacial acetic acid. A sterile Muller Hinton broth containing zinc oxide nanoparticles served as a positive control, whereas a sterile Muller Hinton broth containing solely bacterial isolates served as a negative control.

Effect of Manganese Oxide Nanoparticles on Extracellular Polymeric Substance (EPS) Production

Extraction of EPS

To check the production of EPS by *Klebsiella pneumoniae*, Muller-Hinton broth medium was used. Overnight cultures of tested bacterial isolates were prepared and diluted to make a final concentration of around 0.5 McFarland (1.5×10^8 CFU/ml). The standardised inoculum was distributed into flasks containing 100ml of media with sub-inhibitory doses of metallic nanoparticles in relation to each isolate. The medium without nanoparticles was used as a control. For 24 hours, the flasks were put in a shaking incubator at 37°C. After incubation, flasks were removed and EPS was obtained according to the procedure of De Vuyst et al. (1998). To extract EPS, at 4°C, bacterial cultures were centrifuged at 10,000 rpm for 15 minutes. After centrifugation, the supernatant was removed in a separate flask and kept in a refrigerator overnight. The precipitation of EPS was done by dispensing two volumes of acetone in each flask, followed by overnight refrigeration. To obtain the EPS product, the mixture was centrifuged (at 10,000 rpm at 4°C/15 min). The supernatant was removed, and the pellet obtained was oven dried at 40°C for 24 h. The dry and wet weight of extracted EPS was measured.

Evaluation of anticancer activity of Manganese oxide nanoparticles

Anticancer activity of manganese oxide nanoparticles was checked using 3-(4, 5 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) assay by adopting the method of Jeevanandam et al. (2019) with some modifications. We used HepG2 human liver cell lines; the cells were maintained in a suitable medium.

The cell density was 2×10^4 cells/mL for anticancer potential assays. A 96-well plate was used for experimentation, 100 μ L cells were dispensed into each well and treated with different amounts (500, 400, and 300 μ g/ml) of nanoparticles, a negative control was also used in this assay (without nanoparticles treatment), and incubated for 24 hours under suitable conditions. The sample with the medium was taken from the wells after the incubation period, and the cells were rinsed with PBS (pH 7.4). Following that, 10 μ M MTT dye (5 mg/ml) was applied to each well and incubated for 4 hours before adding 150 μ L DMSO to each well to determine optical density (OD) at 590 nm using a reader plate. Each experiment was carried out in three, and the findings were reported as a mean. The proportion of cells that died was determined using the calculation below.

$$\% \text{age cell death} = \frac{\text{Control} - \text{Treated}}{\text{Control}} \times 100$$

Results

Biochemical Characterization of Bacterial Isolates. The biochemical characterization of bacterial isolates was done by Gram staining and biochemical tests. **Gram Staining.** The stained slides were washed, dried, and observed under an oil immersion lens of a light microscope after the addition of cedar wood oil on the smear. Gram-negative rods (*Klebsiella pneumoniae*) were identified through Gram staining. **Biochemical Tests:** *Klebsiella pneumoniae* colonies on MacConkey agar plates were pinkish, mucoid, and lactose positive. The citrate utilisation test and the Voges–Proskauer test were used to validate the findings. A bacterial colony was injected onto a citrate agar slant and incubated for 24 hours. Because bacteria used citrate, the colour of the slant changed from green to blue during incubation. This indicated a positive citrate utilisation test. A cherry red hue emerged on the top of the broth when a

few drops of 40 percent KOH and alpha naphthol were added to a tube of MR-VP broth with overnight bacterial growth, indicating a positive result of the VP test. Positive results of both citrate utilization test and Voges–Proskauer test confirmed that the test bacterium was *Klebsiella pneumoniae*. Evaluation of Antibacterial Activity of Manganese Oxide Nanoparticles by Agar Well Diffusion Assay. Antibacterial efficacy of Manganese oxide nanoparticles was evaluated against three bacterial isolates of *Klebsiella pneumoniae* by agar well diffusion assay. The inhibitory zones around each agar well were measured in millimeters. Zones of inhibition of bacterial growth represented bactericidal activity of manganese oxide nanoparticles (Table 4.1).




Figure 4.1. Microscopic images of Gram staining of three different isolates of *Klebsiella pneumoniae*




Figure 4.2. Pinkish mucoid colonies of *Klebsiella pneumonia* isolates on MacConkey agar





Figure 4.3. A change in the color from green to blue indicated a positive citrate utilization test for *Klebsiella pneumoniae*

Table 4.1. Antibacterial activity of MnO nanoparticles.

Bacterial isolates	Zone of inhibition in mm			
	25 µg/ml	50 µg/ml	75 µg/ml	100 µg/ml
A	20	19	23	30
B	13	24	21	28
C	18	22	25	36


**Figure 4.4. Zones of inhibition for bacterial isolates due to antibacterial activity of manganese oxide nanoparticles by agar well diffusion assay**

Determination of Minimum Inhibitory Concentration (MIC) of Manganese Oxide Nanoparticles

Using 96-well microtitration plates, the minimum inhibitory concentration of manganese oxide nanoparticles against *K. pneumoniae* was demonstrated. Using the redox nitro blue tetrazolium chloride (NBT) dye, the MIC values of manganese oxide nanoparticles were obtained. In the presence of living bacterial cells, the colour of the dye changed from yellow to blue, whereas in the absence of viable bacterial cells, the dye remained yellow. The highest MIC was obtained against isolate C, as shown in Figure 4.3. MICs of different isolates are given in Table 4.2.

Table 4.2. Minimum inhibitory concentrations in µg/ml of manganese oxide nanoparticles against selected bacterial isolates

Bacterial isolates	MIC (µg/ml) of manganese oxide nanoparticles
Isolate A	375
Isolate B	375
Isolate C	750


**Figure 4.5. Determination of minimum inhibitory concentration of manganese oxide nanoparticles by broth microdilution technique against Klebsiella pneumoniae using Nitro-blue tetrazolium chloride (NBT) dye. Blue color denoted the presence of metabolically active cells (growth), and yellow color indicated the inhibition of growth of the isolate.**

Determination of Minimum Bactericidal Concentration (MBC) of Manganese Oxide Nanoparticles

Minimum bactericidal concentration was evaluated by sub-culturing the broth dilutions from the MIC well and wells with higher concentrations of nanoparticles than the MIC. The absence of bacterial growth on agar plates was used to determine MBC values. Bacterial growth was seen on agar plates using broth containing nanoparticles at the lowest inhibitory concentration. However, no bacterial growth was seen on agar plates containing nanoparticle quantities greater than the minimal inhibitory concentration. MBCs of different isolates are given in Table 4.3

Table 4.3. Minimum bactericidal concentrations (µg/ml) of manganese oxide nanoparticles against selected bacterial isolates.

Bacterial isolates	MBC (µg/ml) of manganese oxide nanoparticles
Isolate A	750
Isolate B	750
Isolate C	1500

**Figure 4.6. Minimum bactericidal concentrations (MBC) of manganese oxide nanoparticles against Klebsiella pneumoniae A, B, and C. 750µg/ml was the least concentration at which MBC was observed**

Evaluation of Antioxidant Activity of Manganese Oxide Nanoparticles
DPPH radical scavenging assay is a quick and easy method to estimate the antioxidant potential of nanoparticles with the use of a spectrophotometer. It was observed that the radical scavenging potential of manganese oxide nanoparticles increased with the increase in the quantity of nanoparticles. A noteworthy increase was observed at the concentration of 200µg/ml, but this was a little less than that of ascorbic acid. The % scavenging activity of manganese oxide nanoparticles ranged from 15 to 65 %. Effect of Manganese Oxide Nanoparticles on Preformed Biofilms

Antibiofilm potential of manganese oxide nanoparticles against preformed biofilms was evaluated by the use of the microtiter plate method. Antibiofilm potential was evaluated against pre-established biofilms. Absorbance results showed that the biofilm inhibition was dependent upon the concentration of nanoparticles used. The percentage inhibition of biofilm was increased with a greater concentration of nanoparticles.

Results showed that the percentage inhibition produced by manganese oxide nanoparticles was found to be 30.14-54.89% when a sub-inhibitory concentration of nanoparticles (0.5 x MIC) was used. On the other hand, the percentage inhibition was 40-59.78%, with (1 x MIC) concentration of nanoparticles. The percentage inhibition of biofilm formation ranged from 30 to 59.78%.

Effect of Manganese Oxide Nanoparticles on the Production of Extracellular Polymeric Substance (EPS)

From cultures of *Klebsiella pneumoniae* isolates (A, B, and C), EPS was extracted using acetone after treatment of bacterial cultures with sub-inhibitory concentrations of manganese oxide nanoparticles. Cultures growing in the absence of sub-inhibitory concentrations of manganese oxide nanoparticles were used as controls. Wet and dry weights of EPS were measured after extraction, and the influence of manganese oxide nanoparticles on EPS production was found. Table 4.4 shows that in cultures developing in the presence of sub-inhibitory doses of manganese oxide nanoparticles, there was a reduction in the quantity of extracted EPS compared to control cells.

The findings revealed that the percentage decrease in the wet weight (mg/100ml) of EPS was 46.6-61.5 percent, while the percentage reduction in the dry weight of EPS was 41.1-61.3 percent. After treatment with manganese oxide nanoparticles, isolate A showed the greatest reduction in wet and dry weight of EPS, whereas isolate A showed the least reduction in wet and dry weight of extracted EPS (Table 4.4).

Evaluation of anti-cancer activity of manganese oxide nanoparticles

Anticancer activity of manganese oxide nanoparticles was evaluated following the MTT method. Different concentrations (500µg/ml, 4000µg/ml, and 300µg/ml) of manganese oxide nanoparticles were used. Results showed that the anti-cancer activity of manganese oxide nanoparticles was dose-dependent (Figure 4.7.B). Percentage % viability as determined by measuring absorbance was found to be 44.48-51.56%, 51.67-60%, 56.82-60.54% at the concentrations of 300µg/ml, 400µg/ml, and 500µg/ml respectively. Maximum anticancer activity was observed at the concentration of 500µg/ml (Figure 4.7.A-4.7.C)




Figure 4.7. MICs and MBCs of manganese oxide nanoparticles against *K. pneumoniae*




Figure 4.8. % scavenging activity of manganese oxide nanoparticles. Ascorbic acid was used as a standard compound




Figure 4.9. Effect of MnO nanoparticles on biofilm formation of *K. pneumoniae* with (0.5x MIC) concentration of nanoparticles




Figure 4.10. Effect of MnO nanoparticles on biofilm formation of *K. pneumoniae* with (1x MIC) concentration of nanoparticles




Figure 4.11. Effect of sub-inhibitory concentrations (0.5xMIC) of MnO nanoparticles on established biofilm of *K. pneumonia*




Figure 4.12. Effect of sub-inhibitory concentrations (1xMIC) of MnO nanoparticles on established biofilm of *K. pneumoniae*




Figure: 4.13. Determination of anti-biofilm activity of manganese oxide nanoparticles against *Klebsiella pneumoniae* isolates K1 (*Klebsiella pneumoniae* A), K2 (*Klebsiella pneumoniae* B), K3 (*Klebsiella pneumoniae* C) by microtiter plate assay





Figure: 4.14. Anti-cancer activity of magnesium oxide nanoparticles against liver cancerous cell line cells

Table 4.4. Wet and dry weight of EPS recovered from *Klebsiella pneumoniae* isolates treated with and without MnO NPs at sub-inhibitory doses (mg/ 100 ml of culture).

Bacterial Isolates	Control (Without Nanoparticles)		Treated cells (MnO)	
	Wet weight	Dry weight	Wet weight	Dry weight
A	39 mg	59 mg	24 mg	36.2 mg
B	42 mg	36 mg	22 mg	24.7 mg
C	45 mg	43.7 mg	21 mg	18 mg

**Figure 4.15. Kinetics of viability of cells treated with different concentrations of manganese oxide nanoparticles**

Discussion

Nanotechnology has revolutionised aerospace engineering, biology, and electronic sectors based on electrical and physiochemical characteristics (18). Nanoparticles have also acquired popularity in medical sectors, such as the pharmaceutical business, where they are used to transport monoclonal antibodies, DNA, proteins, and medicines (19). Present study evaluated antibacterial, antioxidant, antibiofilm and anticancer activity of manganese oxide (MnO) nanoparticles against the three isolates of *Klebsiella pneumoniae* which were chemically characterized by performing biochemical tests. These bacteria were obtained from Department of Microbiology, Government College University Faisalabad. Similar to the current study, Rinita et al., (2021) also prepared MnONPs by biogenic method and obtained NPs were further characterized by scanning electron microscopy (20). Results revealed that regular geometric shapes and coryndrum spheres of NPs with diameter of 10 to 20 µm were obtained and it was also observed that shape and morphology of these NPs could be monitored via controlling the pressure and temperature conditions (21). In another study by Medina-Cruz, (2021) an isolated aerobic bacteria from Persian Gulf water was used to make MnO NPs (22). This isolate belonged to a gram-negative *Acinetobacter* that generated nano Mn-oxide crystal particles, according to 16SRNA sequencing. TEM, SEM, EDAX, XRD, and FTIR were used to characterise the complement morphology, size, and chemical structure of these particles.

In current research anticancer activity of manganese oxide nanoparticles was evaluated against HepG2 human liver cell lines. Results showed that manganese oxide nanoparticles have ability of anticancer activity in dose dependant manners (11). Percentage of cancer cells death was 44.48-51.56%, 51.67-60% and 56.82-60.54% at the concentrations of 300µg/ml, 400µg/ml and 500µg/ml receptively. In order to study the cytotoxicity and safety of metallic nanoparticles (MnO) for human beings, cancerous liver cells were used (23). Cell viability assay using neutral red dye revealed 90-96 % viability cells treated with manganese oxide nanoparticles as

compared to control at a concentration of above 100 µg/ml. Cytotoxicity experiments revealed that the metallic oxide nanoparticles were safer to use for human beings upto that concentration (24). In another study by Uski et al., (2017) cytotoxic assay (MTT) was performed for copper, zinc, titania-zirconia based NPs, ceria, alumina and tungsten carbide NPs against human macrophage cell lines and alveolar epithelium cells (25). The results revealed that Cu and Zn nanoparticles appeared to be more toxic for human cells while alumina, zirconia and ceria based NPs showed mild to moderate toxicity against human cells while no toxicity was observed for tungsten carbide NPs.

Agar well diffusion technique was performed to evaluate the antibacterial potential of manganese oxide nanoparticles. Different concentrations (50, 40, 30, 20, 10, 5, 2.5, 1.25 µg/ml) of MnO nanoparticles were used against isolates. Antibacterial activity increased by increase in concentration of nanoparticles (26). Naumenko et al. (2015) conducted study on antibacterial activity of Manganese Oxide nano particles using concentrations of 39, 78, 156, 312, 625 and 1250 µg ml⁻¹ (27). Using the Broth Microdilution Method, the antibacterial activity of different concentrations of Mn₃O₄-NPs against human pathogenic bacteria, namely *Escherichia coli* and *Staphylococcus aureus*, were investigated. Similarly, antibacterial activity of magnesium oxide nanoparticles was performed by Hayat et al. (2018) against different strains of *Klebsiella pneumoniae* and *E.coli*. Different concentrations (500 µg/mL, 1000 µg/mL and 2000 µg/mL) of nanoparticles were used and maximum zone of inhibition was observed at the concentration of 2000 µg/mL (28). In another study Khan et al. (2020) antibacterial activity of magnesium oxide nanoparticles was evaluated against gram-positive (*Streptococcus pyogenes*, *Staphylococcus aureus*, *Staphylococcus epidermidis*) and gram-negative (*Klebsiella pneumoniae*, *Serratia mercersens* *Pseudomonas aeruginosa*, *Escherichia coli*) (29). Maximum zone of inhibition was measured at the concentration of 25µg/ml that was the highest.

In present study antioxidant potential of manganese oxide nanoparticles was evaluated by using DPPH radical scavenging assay which explained that the antioxidant potential of nanoparticles increased by increase in the

concentration of nanoparticles (30). It was calculated by formula that % scavenging activity of four different concentrations (50, 100, 150 and 200 µg/ml) of nanoparticles was 15, 35, 53 and 65 % respectively. The % scavenging potential of same concentrations of ascorbic acid was higher (26, 44, 64 and 71 %) than % scavenging potential of nanoparticles. Nazir et al., (2020) did a similar investigation on the antioxidant and antibacterial properties of silver and manganese dioxide nanoparticles. Using the conventional well diffusion technique, AgNPs and MnO₂NPs were evaluated for antibacterial activity against human pathogenic *Enterococcus faecalis* ATCC 29212, *Escherichia coli* ATCC 35218, ATCC 25922, *Klebsiella pneumonia* ATCC 700603, and *Staphylococcus aureus* ATCC 43300 and ATCC 29213 (31). MnO₂NPs showed higher antioxidant activity than AgNPs, indicating that the capping agent affects the size and shape of nanoparticles, which affects antioxidant activity (32). Current study determined antibiofilm activity of manganese oxide nanoparticles by microtiter plate assay. It was observed that the sub inhibitory concentrations of manganese oxide nanoparticles exhibited good antibiofilm activity and also treated the mature biofilms efficiently by targeting biofilm viability, biomass and matrix (33). The results of current studies indicated that the antibiofilm potential of manganese oxide nanoparticles depended upon time of nanoparticles-bacterial surface interactions i.e. biofilm inhibition was greater at 24 hours and 48 and 72 hours. Study by Ogunyemi, et al., (2023) demonstrated that manganese oxide nanoparticles exhibited antibiofilm activity against Xoo strain GZ 0006. It was stated that the nanoparticles can inhibit the formation of biofilm but have lower efficacy of inhibition on the preformed biofilms (34).

Effect of sub-inhibitory concentrations of metallic nanoparticles on extracellular polymeric substance (EPS) extracted from various isolates was determined (35). The results indicated a considerable reduction in wet and dry weight of EPS. Similarly, there was a decrease in protein and carbohydrate contents of extracted EPS from cells growing in the presence of manganese oxide nanoparticles. In a study by Gangadhar et al., (2022), it was observed that NPs caused reduction in EPS (36). The entire findings of the current research work specified that manganese oxide (MnO) nanoparticles have wonderful potentials such as antibacterial, antioxidant and antibiofilm activities against multidrug resistant *Klebsiella pneumonia* (14). Manganese oxide nanoparticles can be used in combination to different antibiotics for enhanced antibacterial effect against the multidrug resistant bacteria (9).

Overall findings of the current research work illustrated that manganese oxide (MgO) nanoparticles have marvelous potential of anti-biofilm, antibacterial and antioxidant activities against multidrug resistance three strains of *Klebsiella pneumonia* (37). Cytotoxicity experiment revealed that manganese oxide nanoparticles were safer to use for human beings. More research work is needed to determine anti-biofilm and antibacterial potential of manganese oxide nanoparticles against other human pathogens (38). Moreover, cytotoxicity assays should be extended to other human cell lines to confirm the safety of these nanoparticles for human beings (39).

Conclusion

Biogenically synthesized manganese oxide nanoparticles possess potent antibacterial and antibiofilm activity against *Klebsiella pneumoniae*, with minimal cytotoxicity to human liver cells. These findings suggest that MnO NPs may offer a promising alternative therapeutic approach to combat multidrug-resistant bacterial infections.

Declarations

Data Availability statement

All data generated or analysed during the study are included in the manuscript.

Ethics approval and consent to participate

Approved by the department concerned. (IRBEC-MMNCS-0331d-24)

Consent for publication

Approved

Funding

Not applicable

Conflict of interest

The authors declared the absence of a conflict of interest.

Author Contribution

MN

Manuscript drafting, Study Design,

AG

Review of Literature, Data entry, Data analysis, and drafting article.

AA

Conception of Study, Development of Research Methodology Design,

QY

Study Design, manuscript review, critical input.

STZN

Manuscript drafting, Study Design,

AB

Review of Literature, Data entry, Data analysis, and drafting article.

NM

Conception of Study, Development of Research Methodology Design,

HSY

Study Design, manuscript review, critical input

All authors reviewed the results and approved the final version of the manuscript. They are also accountable for the integrity of the study.

References

1. Saleem M, Deters B, de la Bastide A, Korzen M. Antibiotics overuse and bacterial resistance. *Annals of Microbiology and Research*. 2019;3(1):93. [DOI: 10.36959/958/573](https://doi.org/10.36959/958/573)
2. Mohammed W, Awad FA, Mustafa TI. The importance of *Klebsiella pneumoniae* as a pathogen and the increasing prevalence of antibiotic-resistant strains and molecular characteristics. *Baghdad Journal of Biochemistry and Applied Biological Sciences*. 2023;4(4):180-203. [DOI: https://doi.org/10.47419/bjabs.v4i04.211](https://doi.org/10.47419/bjabs.v4i04.211)
3. Mohd Asri NA, Ahmad S, Mohamud R, Mohd Hanafi N, Mohd Zaidi NF, Irekeola AA, et al. Global prevalence of nosocomial multidrug-resistant *Klebsiella pneumoniae*: a systematic review and meta-analysis. *Antibiotics*. 2021;10(12):1508. <https://doi.org/10.3390/antibiotics10121508>
4. Pugazhendhi AS, Wei F, Hughes M, Coathup M. Bacterial adhesion, virulence, and biofilm formation. *Musculoskeletal Infection: Springer*; 2022. p. 19-64. <https://doi.org/10.4161/biom.22905>
5. Tarin-Pello A, Suay-Garcia B, Perez-Gracia M-T. Antibiotic resistant bacteria: current situation and treatment options to accelerate the development of a new antimicrobial arsenal. Expert review of anti-infective therapy. 2022;20(8):1095-108. <https://doi.org/10.1080/14787210.2022.2078308>
6. Altun E, Aydogdu MO, Chung E, Ren G, Homer-Vanniasinkam S, Edirisinghe M. Metal-based nanoparticles for combating antibiotic resistance. *Applied Physics Reviews*. 2021;8(4). <https://doi.org/10.1063/5.0060299>
7. Xie M, Gao M, Yun Y, Malmsten M, Rotello VM, Zboril R, et al. Antibacterial nanomaterials: mechanisms, impacts on antimicrobial resistance and design principles. *Angewandte Chemie International Edition*. 2023;62(17):e202217345. <https://doi.org/10.1002/anie.202217345>
8. Alavi M, Rai M. Recent advances in antibacterial applications of metal nanoparticles (MNPs) and metal nanocomposites (MNCs) against multidrug-resistant (MDR) bacteria. Expert review of anti-infective therapy. 2019;17(6):419-28. <https://doi.org/10.1080/14787210.2019.1614914>
9. Abdullah, Jamil T, Atif M, Khalid S, Metwally K, Yahya G, et al. Recent advances in the development of metal/metal oxide nanoparticle and antibiotic conjugates (MNP-antibiotics) to address antibiotic resistance: review

and perspective. International Journal of Molecular Sciences. 2024;25(16):8915.

<https://doi.org/10.3390/ijms25168915>

10. Velho-Pereira S, Parmekar MV. Synthesis and Antibacterial Properties of Manganese Dioxide Nanostructures: A Review. ChemistrySelect. 2024;9(38):e202402247. <https://doi.org/10.1002/slct.202402247>

11. Sobańska Z, Roszak J, Kowalczyk K, Stępnik M. Applications and biological activity of nanoparticles of manganese and manganese oxides in vitro and in vivo models. Nanomaterials. 2021;11(5):1084. <https://doi.org/10.3390/nano11051084>

12. Singh N, Savanur MA, Srivastava S, D'Silva P, Mugesh G. A manganese oxide nanozyme prevents the oxidative damage of biomolecules without affecting the endogenous antioxidant system. Nanoscale. 2019;11(9):3855-63. <https://doi.org/10.1039/C8NR09397K>

13. Xu W, Qing X, Liu S, Chen Z, Zhang Y. Manganese oxide nanomaterials for bacterial infection detection and therapy. Journal of Materials Chemistry B. 2022;10(9):1343-58. [DOI https://doi.org/10.1039/D1TB02646A](https://doi.org/10.1039/D1TB02646A)

14. AboKsour MF, Al-Marjani MF, Rheima AM. Preparation and Effects of Manganese Oxide Nanoparticles Against Quinolone-Resistant Bacteria Isolated from Hospital Wastewater. Al-Rafidain Journal of Medical Sciences (ISSN 2789-3219). 2024;6(2):94-100. [DOI: https://doi.org/10.54133/ajms.v6i2.728](https://doi.org/10.54133/ajms.v6i2.728)

15. Sharma RP, Raut SD, Jadhav VV, Mulani RM, Kadam AS, Mane RS. Assessment of antibacterial and anti-biofilm effects of zinc ferrite nanoparticles against Klebsiella pneumoniae. Folia Microbiologica. 2022;67(5):747-55. <https://doi.org/10.2147/IDR.S453025>

16. Ashraf H, Meer B, Iqbal J, Ali JS, Andleeb A, Butt H, et al. Comparative evaluation of chemically and green synthesized zinc oxide nanoparticles: their in vitro antioxidant, antimicrobial, cytotoxic and anticancer potential towards HepG2 cell line. Journal of Nanostructure in Chemistry. 2023;13(2):243-61. [DOI https://doi.org/10.1007/s40097-021-00460-3](https://doi.org/10.1007/s40097-021-00460-3)

17. Barani M, Fathizadeh H, Arkaban H, Kalantar-Neyestanaki D, Akbarizadeh MR, Turki Jalil A, et al. Recent advances in nanotechnology for the management of Klebsiella pneumoniae-related infections. Biosensors. 2022;12(12):1155. <https://doi.org/10.3390/bios12121155>

18. Malik S, Muhammad K, Waheed Y. Nanotechnology: a revolution in modern industry. Molecules. 2023;28(2):661. <https://doi.org/10.3390/molecules28020661>

19. Joseph TM, Kar Mahapatra D, Esmaeili A, Piszczek Ł, Hasanin MS, Kattali M, et al. Nanoparticles: taking a unique position in medicine. Nanomaterials. 2023;13(3):574. <https://doi.org/10.3390/nano13030574>

20. Rinita J, Jose R, Jothi NN. Acclimated growth and characterization of manganese oxide nanospheres using natural extract from trigonella foenum-graecum. Materials Technology. 2021;36(7):412-9. [DOI: 10.1080/10667857.2020.1761660](https://doi.org/10.1080/10667857.2020.1761660)

21. Senthilkumar N, Aravindhan V, Ruckmani K, Potheher IV. Coriandrum sativum mediated synthesis of silver nanoparticles and evaluation of their biological characteristics. Materials Research Express. 2018;5(5):055032. [DOI 10.1088/2053-1591/aac312](https://doi.org/10.1088/2053-1591/aac312)

22. Medina-Cruz D, Saleh B, Vernet-Crua A, Nieto-Argüello A, Lomeli-Marroquín D, Vélez-Escamilla LY, et al. Bimetallic nanoparticles for biomedical applications: A review. Racing for the Surface: Antimicrobial and Interface Tissue Engineering. 2020:397-434. <https://doi.org/10.1016/j.copbio.2018.01.029>

23. Strasser A, Vaux DL. Cell death in the origin and treatment of cancer. Molecular cell. 2020;78(6):1045-54. [DOI: 10.1016/j.molcel.2020.05.014](https://doi.org/10.1016/j.molcel.2020.05.014)

24. Johnston LJ, Du X, Zborowski A, Kennedy DC. Characterization and cellular toxicity studies of commercial manganese oxide nanoparticles. Nanomaterials. 2024;14(2):198. <https://doi.org/10.3390/nano14020198>

25. Uski O, Torvela T, Sippula O, Karhunen T, Koponen H, Peräniemi S, et al. In vitro toxicological effects of zinc containing nanoparticles with different physico-chemical properties. Toxicology in vitro. 2017;42:105-13. <https://doi.org/10.1016/j.tiv.2017.04.010>

26. Nalawade TM, Bhat KG, Sogi S. Antimicrobial activity of endodontic medicaments and vehicles using agar well diffusion method on facultative and obligate anaerobes. International journal of clinical pediatric dentistry. 2016;9(4):335. [doi: 10.5005/ip-journals-10005-1388](https://doi.org/10.5005/ip-journals-10005-1388)

27. Naumenko E, Guryanov I, Gomzikova M. Drug delivery nano-platforms for advanced cancer therapy. Scientia Pharmaceutica. 2024;92(2):28. <https://doi.org/10.3390/scipharm92020028>

28. Hayat S, Ashraf A, Zubair M, Aslam B, Siddique MH, Khurshid M, et al. Biofabrication of ZnO nanoparticles using Acacia arabica leaf extract and their antibiofilm and antioxidant potential against foodborne pathogens. PLoS One. 2022;17(1):e0259190. <https://doi.org/10.1371/journal.pone.0259190>

29. Khan A, Shabir D, Ahmad P, Khandaker MU, Faruque M, Din IU. Biosynthesis and antibacterial activity of MgO-NPs produced from Camellia-

sinensis leaves extract. Materials Research Express. 2020;8(1):015402. <https://iopscience.iop.org/article/10.1088/2053-1591/abd421/meta>

30. Pardhiya S, Priyadarshini E, Rajamani P. In vitro antioxidant activity of synthesized BSA conjugated manganese dioxide nanoparticles. SN Applied Sciences. 2020;2(9):1597. <https://doi.org/10.1007/s42452-020-03407-5>

31. Nazir S, Jan H, Zaman G, Khan T, Ashraf H, Meer B, et al. Copper oxide (CuO) and manganese oxide (MnO) nanoparticles induced biomass accumulation, antioxidants biosynthesis and abiotic elicitation of bioactive compounds in callus cultures of Ocimum basilicum (Thai basil). Artificial Cells, Nanomedicine, and Biotechnology. 2021;49(1):625-33. <https://doi.org/10.1080/21691401.2021.1984935>

32. Abuzeid HM, Julien CM, Zhu L, Hashem AM. Green Synthesis of Metal and Metal Oxide Nanoparticles for Recent Applications. 2023. [doi: 10.20944/preprints202310.1164.v1](https://doi.org/10.20944/preprints202310.1164.v1)

33. Safaei M, Moghadam A. A new green method for synthesis of manganese oxide nanoparticles as antibacterial agent against oral biofilm. Journal of Nanostructures. 2023;13(3):693-702. [10.22052/JNS.2023.03.010](https://doi.org/10.22052/JNS.2023.03.010)

34. Ogunyemi SO, Abdallah Y, Ibrahim E, Zhang Y, Bi Ja, Wang F, et al. Bacteriophage-mediated biosynthesis of MnO₂NPs and MgONPs and their role in the protection of plants from bacterial pathogens. Frontiers in Microbiology. 2023;14:1193206. <https://doi.org/10.3389/fmicb.2023.1193206>

35. Garza-Cervantes JA, Mendiola-Garza G, León-Buitimea A, Morones-Ramírez JR. Synergistic antibacterial effects of exopolysaccharides/nickel-nanoparticles composites against multidrug-resistant bacteria. Scientific Reports. 2023;13(1):21519. <https://doi.org/10.1038/s41598-023-48821-y>

36. Gangadhar L, Abhishek N, Venkatesh M, Prasad V, Nagendra PS, Mekapogu M, et al. Bacterial synthesis of zinc oxide nanoparticles and their applications. Biogenic Sustainable Nanotechnology: Elsevier; 2022. p. 293-313. <https://doi.org/10.1016/B978-0-323-88535-5.00010-X>

37. Moradi F, Ghaedi A, Fooladfar Z, Bazrgar A. Recent advance on nanoparticles or nanomaterials with anti-multidrug resistant bacteria and antibacterial biofilm properties: A systematic review. Heliyon. 2023;9(11). [DOI: 10.1016/j.heliyon.2023.e22105](https://doi.org/10.1016/j.heliyon.2023.e22105)

38. Elharrif MG, Hassan NA, Sharaf M. Biosynthesis of novel MnO₂ nanocapsules via C. spinosa extract and honeybee-derived chitosan: exploring antibacterial and anticancer properties. Russian Journal of Infection and Immunity. 2024;14(5):1002-16. [DOI: https://doi.org/10.15789/2220-7619-BON-17582](https://doi.org/10.15789/2220-7619-BON-17582)

39. Kus-Liśkiewicz M, Fickers P, Ben Tahar I. Biocompatibility and cytotoxicity of gold nanoparticles: recent advances in methodologies and regulations. International journal of molecular sciences. 2021;22(20):10952. <https://doi.org/10.3390/ijms22010952>



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, <http://creativecommons.org/licenses/by/4.0/>. © The Author(s) 2025